Fixed Drug Eruption due to Dupilumab.
Ayaka Kaneoka; Natsuko Saito-Sasaki; Yumiko Sakuragi; Yu Sawada
Acta dermato-venereologica, Apr. 2024, Reviewed, No invitation
Lead

Ixekizumab-induced urticarial drug eruption.
Ayaka Kaneoka; Natsuko Saito-Sasaki; Etsuko Okada; Yu Sawada
Skin health and disease, Oct. 2023

STING expression is an independent prognostic factor in patients with mycosis fungoides.
Reiko Takayanagi-Hara; Yu Sawada; Hitomi Sugino; Yoko Minokawa; Hikaru Kawahara-Nanamori; Misa Itamura; Tomoko Tashiro; Ayaka Kaneoka; Natsuko Saito-Sasaki; Kayo Yamamoto; Etsuko Okada
Scientific reports, Jul. 2022

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.
Ayaka Kaneoka; Etsuko Okada; Hitomi Sugino; Natsuko Saito-Sasaki; Daisuke Omoto; Motonobu Nakamura
Diagnostics (Basel, Switzerland), Feb. 2022

[A Case of Pemphigus Vulgaris Showing a Local Nose Erosion as the First Clinical Manifestation].
Ayaka Kaneoka; Yu Sawada
Journal of UOEH, 2022

Angioimmunoblastic T-cell Lymphoma (AITL)の1例
金岡亜也加，赤松洋子，原礼子，杉山暁子，瀬戸口美保子
産業医科大学雑誌, Sep. 2022, Reviewed, Null
Lead

鼻部限局のびらんを初発とした抗デスモグレイン１抗体ならびに抗デスモグレイン3抗体陽性の尋常性天疱瘡の1例
金岡亜也加, 澤田雄宇
JOURNALOF UOEH, Jun. 2022, Reviewed, Null
Lead

左鼠径部い生じたcellular angiofibromaの1例
金岡亜也加, 片山絢子, 岡田悦子, 中村元信
西日本皮膚科, Jun. 2019, Null, Null
Lead

Nivolumab、dabrafenib/trametinib投与中に急激な血小板低下を来した悪性黒色腫の1例
金岡亜也加, 瀬戸山絢子, 山口卓, 吉岡学, 岡田悦子, 中村元信
西日本皮膚科, Apr. 2019, Null, Null
Lead

Fixed Drug Eruption due to Dupilumab.
Kaneoka Ayaka, Saito-Sasaki Natsuko, Sakuragi Yumiko, Sawada Yu
Acta dermato-venereologica, Apr. 2024, Null, Null
Lead

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
Kaneoka Ayaka, Okada Etsuko, Sugino hitomi, Saito-Sasaki Natsuko, Omoto Daisuke, and Nakamura Motonobu
Diagnostics, Feb. 2022, Reviewed, Null
Lead

Ixekizumab-induced urticarial drug eruption.
Kaneoka Ayaka, Saito-Sasaki Natsuko, Okada Etsuko, Sawada Yu
Skin health and disease, Oct. 2023, Null, Null
Lead